文献
J-GLOBAL ID:201202285091963649
整理番号:12A0323011
数十年間のラット発癌性試験の薬学的知識の分析: 現在の規定ガイドラインを修正する提案の支持
An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing: Support for a Proposal to Modify Current Regulatory Guidelines
著者 (39件):
SISTARE Frank D.
(Merck and Co., Inc., Pennsylvania, USA)
,
MORTON Daniel
(Pfizer, Connecticut, USA)
,
ALDEN Carl
(Millenium, Massachusetts, USA)
,
CHRISTENSEN Joel
(Merck and Co., Inc., Pennsylvania, USA)
,
KELLER Douglas
(Sanofi Aventis, Pennsylvania, USA)
,
DE JONGHE Sandra
(Janssen Pharmaceutica NV, Beerse, BEL)
,
STORER Richard D.
(Merck and Co., Inc., Pennsylvania, USA)
,
REDDY M. Vijayaraj
(Merck and Co., Inc., Pennsylvania, USA)
,
KRAYNAK Andrew
(Merck and Co., Inc., Pennsylvania, USA)
,
TRELA Bruce
(Abbott Lab., Illinois, USA)
,
BIENVENU Jean-Guy
(Lab Res., Quebec, CAN)
,
BJURSTROEM Sivert
(AstraZeneca R & D, Soedertaelje, SWE)
,
BOSMANS Vanessa
(Janssen Pharmaceutica NV, Beerse, BEL)
,
BREWSTER David
(Hoffman-La Roche, New Jersey, USA)
,
COLMAN Karyn
(Novartis Pharmaceutical Corp., New Jersey, USA)
,
DOMINICK Mark
(Bristol-Myers Squibb, Indiana, USA)
,
EVANS John
(AstraZeneca R & D, Soedertaelje, SWE)
,
HAILEY James R.
(GlaxoSmithKline, North Carolina, USA)
,
KINTER Lewis
(AstraZeneca R & D, Soedertaelje, SWE)
,
KINTER Lewis
(AstraZeneca R & D, Delaware, USA)
,
LIU Matt
(Merck and Co., Inc., Pennsylvania, USA)
,
MAHRT Charles
(Eli Lilly & Co., Inc., Indiana, USA)
,
MARIEN Dirk
(Janssen Pharmaceutica NV, Beerse, BEL)
,
MYER James
(GlaxoSmithKline, North Carolina, USA)
,
PERRY Richard
(Pfizer, Connecticut, USA)
,
POTENTA Daniel
(Novartis Pharmaceutical Corp., New Jersey, USA)
,
ROTH Arthur
(Pfizer, Connecticut, USA)
,
SHERRATT Philip
(Merck and Co., Inc., Pennsylvania, USA)
,
SINGER Thomas
(Hoffman-La Roche, New Jersey, USA)
,
SINGER Thomas
(Hoffman-La Roche, Basel, CHE)
,
SLIM Rabih
(Hoffman-La Roche, New Jersey, USA)
,
SOPER Keith
(Merck and Co., Inc., Pennsylvania, USA)
,
FRANSSON-STEEN Ronny
(AstraZeneca R & D, Soedertaelje, SWE)
,
STOLTZ James
(Boehringer Ingelheim Pharmaceuticals, Inc., Connecticut, USA)
,
TURNER Oliver
(Novartis Pharmaceutical Corp., New Jersey, USA)
,
TURNQUIST Susan
(Pfizer, Connecticut, USA)
,
VAN HEERDEN Marjolein
(Janssen Pharmaceutica NV, Beerse, BEL)
,
WOICKE Jochen
(Bristol-Myers Squibb, Indiana, USA)
,
DEGEORGE Joseph J.
(Merck and Co., Inc., Pennsylvania, USA)
資料名:
Toxicologic Pathology
(Toxicologic Pathology)
巻:
39
号:
4
ページ:
716-744
発行年:
2011年06月
JST資料番号:
T0222A
ISSN:
0192-6233
資料種別:
逐次刊行物 (A)
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)